Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.

Autor: Mortimer J, Livingston RB, Hardesty IJ, Groppe CW Jr, Purvis JD 3rd, Gupta M, Flournoy N
Jazyk: angličtina
Zdroj: Cancer treatment reports [Cancer Treat Rep] 1984 Jul-Aug; Vol. 68 (7-8), pp. 1017-8.
Abstrakt: Twenty-seven women with disseminated estrogen receptor-negative breast cancer received an aggressive chemotherapy program of prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide. Responses were achieved in 21 of 26 (81%) evaluable patients, eight (31%) of whom had complete responses. The median survival was 17 months. Despite the favorable overall response and a significant number of complete responses, all patients eventually relapsed. Although most patients relapsed systematically, two relapsed initially in the CNS.
Databáze: MEDLINE